Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET

Company Participants

James Carbonara - Hayden IR

Jennifer Simpson - President & CEO

Sue Horvath - VP & CFO

Conference Call Participants

Jonathan Aschoff - Roth MKM

Operator

Good day, and welcome to the Panbela Therapeutics first-quarter 2023 earnings call. [Operator Instructions]. It is now my pleasure to turn the floor over to your host, Mr. James Carbonara. Sir, the floor is yours.

James Carbonara

Thank you, operator. With me on the call are Jennifer Simpson, Chief Executive Officer; and to Sue Horvath, Chief Financial Officer.

Before I turn the call over to Dr. Simpson, please note that statements made on this call that are not historical facts may be forward-looking statements.

Significant risks and uncertainties that could cause actual results to differ from those expressed or implied in the forward-looking statements are detailed in the company's annual report on Form 10-K and supplemented by subsequently filed quarterly reports on Form 10-Q as well as in other reports that the company has filed with the SEC.

Any forward-looking statements made on this call are made only as of today's date, and the company does not undertake any obligation to update or supplement any such statements to reflect subsequent developments.

Now I would like to turn the call over to Jennifer Simpson, CEO of Panbela. Jennifer, please proceed.

Jennifer Simpson

Thank you, James, and thank you, everyone, for joining. I will begin the call with a review of our clinical development program, recent accomplishments, and upcoming milestones. Sue will then follow with a review of the financial results, and then we will open it up for Q&A.

Starting with our Phase III program, I'd like to begin with our ASPIRE global clinical trial in first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind, placebo-controlled clinical trial to evaluate ivospemin or SBP-101 in combination with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma.

We continue global enrollment and are focused on the country and site initiations for the ASPIRE trial as we aim to have the full complement of sites on board by the middle of this year. Having all three regions, Asia Pacific, Europe, and North America enrolling, with the recent release that South Korea enrolled its first patient, it's highly encouraging as we continue to advance the trial with the interim analysis expected in early 2024.